No additional benefit of HRT on response to rivastigmine in menopausal women with AD
The DOI matches its Crossref record.
Abstract
Rivastigmine is an approved cholinesterase inhibitor with proven efficacy on cognitive and functional deficits in mild to moderately severe AD.1 The possibility that estrogen might enhance effects of cholinergic therapy was previously suggested from post hoc analyses of a 30-week, multicenter trial of tacrine,2 but no results from randomized, placebo-controlled studies are available so far.6 We studied 117 menopausal women with AD ( Diagnostic and Statistical Manual, 4th ed. and National Institute of Neurological and Communicative Diseases and Stroke–AD and Related Disorders Association criteria) and a Mini-Mental State Examination (MMSE) score between 10 and 26 (both inclusive). Patients should not have received hormone replacement therapy (HRT) for the previous 10 years and previous antidementia treatment had been interrupted for at least 3 months. Seventeen centers from France participated in this 28-week, double-blind, placebo-controlled study after approval by the ethics committee (Cochin Hospital, Paris). All patients received rivastigmine (Exelon et Estraderm, Novartis Pharma AG, Stein, Switzerland); after an initial dosage of 1.5 mg twice …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism
Boeve, B. F., Silber, M. H., Parisi, J. E., Dickson, D. W., Ferman, T. J., Benarroch, E. E., Schmeichel, A. M., Smith, G. E., Petersen, R. C., Ahlskog, J. E., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073619.94467.b0 · Cited by 379
The Glutamatergic System and Alzheimer???s Disease: Therapeutic Implications
Butterfield, D. A., & Pocernich, C. B. (2003) · CNS Drugs · doi:10.2165/00023210-200317090-00004 · Cited by 267
Combination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Metadata
- Authors
- Rigaud, A. S., André, G., Vellas, B., Touchon, J., & Pere, J. J.
- Venue
- Neurology
- Published
- 2003-01-14
- Volume
- 60
- Issue
- 1
- Pages
- 148-149
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1999193296
- Cited by
- 38
- References
- 0
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: No additional benefit of HRT on response to rivastigmine in menopausal women with AD. https://app.cochat.ai/papers/10.1212/wnl.60.1.148-a
- The paper
- Rigaud, A. S., André, G., Vellas, B., Touchon, J., & Pere, J. J. (2003). No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology. https://doi.org/10.1212/wnl.60.1.148-a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.